Blog

Surge in coronavirus cases in Patna: Patna to Remain Under Lockdown From July 10 to 16, Essential Services Allowed.

Surge in coronavirus cases in Patna: Patna to Remain Under Lockdown From July 10 to 16, Essential Services Allowed.

Keeping in mind the rising cases of coronavirus, the Patna district administration on Wednesday decided to impose complete lockdown in the state capital from July 10 to 16 to break the chain of the deadly virus. Except for the essential services, markets, offices and other commercial activities will be prohibited during the lockdown period in the state capital, the order said. While 749 cases were reported from Bihar, Patna alone registered 235 Covid-19 cases on Wednesday, which is the highest one day record. Ravi in his order stated that there was an alarming surge in Covid-19 positive cases in Patna…
Read More
Complete lockdown in parts of Siliguri

Complete lockdown in parts of Siliguri

With Covid-19 cases on the rise in north Bengal, the administration in Darjeeling district on Wednesday banned the entry of tourists to the hills till July 31. The Gorkhaland Territorial Administration (GTA) on Wednesday withdrew its earlier decision to allow hotels and tourist spots in Darjeeling and adjoining Kalimpong to operate from July 1. Some hotels have also received guests. Anit Thapa, chairman of board of administrators of GTA, said, “We have decided not to allow tourists in the GTA area from Thursday to July 31 in view of the rising number of Covid-19 cases across the country.”
Read More
Reduction in syllabus a one-time measure, “Has Been Interpreted Differently” , says CBSE.

Reduction in syllabus a one-time measure, “Has Been Interpreted Differently” , says CBSE.

Amid outrage and protests over the changes, the CBSE said the reduction or “rationalization” of syllabus for classes 9 to 12 had been "interpreted differently" and that it was a “one-time measure” to reduce the exam stress of students due to the health emergency and to prevent learning gaps.The national education board was responding to criticism it faced after k ey chapters like Democratic Rights, Food Security in India, Federalism, Citizenship and Secularism have been dropped from school courses to reduce the burden on students amid the coronavirus crisis. “The schools have also been directed to follow the alternative academic…
Read More
Arvind Kejriwal asks Health Secy to share detailed analysis

Arvind Kejriwal asks Health Secy to share detailed analysis

Delhi Chief Minister Arvind Kejriwal has directed Delhi Health Secretary to share a detailed analysis of factors behind all COVID-19 deaths reported in the national capital in the last two weeks. The objective is to take measures to further reduce COVID19 deaths in the national capital which has so far reported 3,165 fatalities due to the highly-contagious disease. Meanwhile, the Delhi government has also directed all government and private COVID hospitals to get feedback from patients and their willingness to donate blood plasma after at the time of discharge.
Read More
Cipla Set To Undercut

Cipla Set To Undercut

Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch. Cipla business chief executive officer and executive vice president Nikhil Chopra said in an emailed statement that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000…
Read More
Amphan: Coca-Cola partners with Save the Children

Amphan: Coca-Cola partners with Save the Children

Coca-Cola in India with funding from The Coca-Cola Foundation has partnered with Save the Children to address the food security and shelter needs of affected victims of Cyclone AMPHAN, through a comprehensive relief assistance programme. The programme was rolled out in Kolkata in the presence of Sourav Ganguly, Mr Hemant Goenka, Managing Director, Diamond Beverages Pvt. Ltd. (DBPL), bottling partner of Coca-Cola in West Bengal. With over 1-lakh households displaced and 6-lakh people evacuated, this initiative will focus on aiding safe and hygienic drinking water, food security, shelter needs and livelihood in East Medinipur, Kolkata and South 24 Paraganas. Through…
Read More
Sony establishes Sony Research India

Sony establishes Sony Research India

Sony Corporation (‘Sony) announced that it established a research company ‘Sony Research India Private Limited’ (Sony Research India) effective July 1, 2020. Sony Research India consists of R&D Center India Bengaluru Laboratory and Mumbai Laboratory as part of Sony’s Global R&D centers. Through the establishment of Sony Research India, Sony will seek to leverage its multi-sites structure and talent for the excellence of its research. Sony Research India also aims to accelerate the collaboration with its entertainment and electronics business groups, while further enhancing competitiveness and capability of research and development in India. Sony Research India is also offering outstanding…
Read More
Glenmark’s Fabiflu for mild to moderate COVID-19 cases

Glenmark’s Fabiflu for mild to moderate COVID-19 cases

Over the past 5 months, since the first reported case of COVID-19, Glenmark mobilized its teams and development process started at its Research and Development (R&D) facility in Navi Mumbai. The entire process from R&D, to producing the Active Pharmaceutical Ingredient (API) at Ankleshwar (Gujarat) and manufacturing the formulations at Baddi (Himachal Pradesh) have been done in-house and is a significant achievement as part of “Make in India”. Despite investing significantly throughout the process of manufacturing FabiFlu, Glenmark has managed to keep the pricing of FabiFlu economical as compared to its price in other countries. FabiFlu in India costs Rs…
Read More
‘Covaxin’ Human Trial Process Begins at Hyderabad’s NIMS, Patna AIIMS

‘Covaxin’ Human Trial Process Begins at Hyderabad’s NIMS, Patna AIIMS

Now that India has developed its first indigenous COVID-19 vaccine, Covaxin, it has started its preparations to begin the much-awaited human clinical trials. Covaxin will be tested on more than 1100 people. The vaccine developed by the Bharat Biotech recently got the green signal from ICMR and the apex body has given nod to a total of 12 hospitals to begin preparations to conduct human clinical trials. Two of them include Hyderabad’s Nizam’s Institute of Medical Sciences and Patna-based All India Institute of Medical Science (AIIMS) As per reports, the human trial will take at least 6 to 8 months to…
Read More
Covaxin trial to start at Belagavi hospital , India’s first COVID-19 vaccine to begin soon.

Covaxin trial to start at Belagavi hospital , India’s first COVID-19 vaccine to begin soon.

Covaxin, the first possible vaccine against COVID-19, will be tested on a team of around 200 healthy volunteers in and around Belagavi. The clinical trials will be conducted by doctors and staff members of Jeevan Rekha, a multi-speciality hospital here, monitored by the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd., the private company that has developed the chemical molecule, doctors at the hospital said. Jeevan Rekha is one of the 12 hospitals and health centres in the country chosen by the Union government for clinical trials of the vaccine, whose technical name is BBV152 COVID vaccine.…
Read More